- Home
- CODA vs CNTX Comparison
CODA vs CNTX Comparison
Compare CODA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODA
- CNTX
- Stock Information
- Founded
- CODA 1994
- CNTX 2015
- Country
- CODA United States
- CNTX United States
- Employees
- CODA N/A
- CNTX N/A
- Industry
- CODA Industrial Machinery/Components
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- CODA Industrials
- CNTX Health Care
- Exchange
- CODA Nasdaq
- CNTX Nasdaq
- Market Cap
- CODA 88.7M
- CNTX 78.0M
- IPO Year
- CODA N/A
- CNTX 2021
- Fundamental
- Price
- CODA $8.11
- CNTX $0.64
- Analyst Decision
- CODA Strong Buy
- CNTX Strong Buy
- Analyst Count
- CODA 1
- CNTX 5
- Target Price
- CODA $11.00
- CNTX $5.50
- AVG Volume (30 Days)
- CODA 62.6K
- CNTX 313.4K
- Earning Date
- CODA 06-16-2025
- CNTX 08-06-2025
- Dividend Yield
- CODA N/A
- CNTX N/A
- EPS Growth
- CODA 21.86
- CNTX N/A
- EPS
- CODA 0.30
- CNTX N/A
- Revenue
- CODA $22,758,966.00
- CNTX N/A
- Revenue This Year
- CODA $11.64
- CNTX N/A
- Revenue Next Year
- CODA $14.53
- CNTX N/A
- P/E Ratio
- CODA $27.03
- CNTX N/A
- Revenue Growth
- CODA 24.78
- CNTX N/A
- 52 Week Low
- CODA $5.76
- CNTX $0.49
- 52 Week High
- CODA $9.89
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- CODA 61.67
- CNTX 49.49
- Support Level
- CODA $7.78
- CNTX $0.62
- Resistance Level
- CODA $8.31
- CNTX $0.70
- Average True Range (ATR)
- CODA 0.57
- CNTX 0.05
- MACD
- CODA 0.05
- CNTX 0.01
- Stochastic Oscillator
- CODA 60.98
- CNTX 57.14
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.